Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 4,666 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Signs and Symptoms Clear all
Recruiting No phase listed Observational

Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC

NCT04528355
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions
Interventions
data collection
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 1 Interventional

Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)

NCT00802555
View directory record Official record
Conditions
Cirrhosis, Hepatocellular Carcinoma
Interventions
ARQ 197
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Oct 15, 2026, 2:04 AM EDT
Completed No phase listed Observational

Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)

NCT00514878
View directory record Official record
Conditions
Nausea, Postoperative Nausea and Vomiting, Postdischarge Nausea and Vomiting, Postoperative Pain
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2009 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 1 Interventional

Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy

NCT01164215
View directory record Official record
Conditions
Colorectal Cancer, Diarrhea, Neutropenia
Interventions
fluorouracil, leucovorin, oxaliplatin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Asheville, North Carolina • Greensboro, North Carolina • Greenville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 15, 2026, 2:04 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Maneuvers to Reduce Laparoscopic Pain

NCT07583433
View directory record Official record
Conditions
Laparoscopic Surgery, Post Operative Pain, Acute, Pneumoperitoneum
Interventions
Smoke Evacuation Group, Recruitment Breath Group, Control Group
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Not applicable Interventional

Nurse-Provided Care or Standard Care in Treating Patients With Pancreatic Cancer

NCT00902733
View directory record Official record
Conditions
Fatigue, Nausea and Vomiting, Pain, Pancreatic Cancer
Interventions
medical chart review, questionnaire administration, fatigue assessment and management, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2010 · Synced Oct 15, 2026, 2:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

NCT07594626
View directory record Official record
Conditions
Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Carcinoma, Stage IV Colon Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Pemetrexed, PRMT5 Inhibitor BMS-986504
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 15, 2026, 2:04 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

NCT06950385
View directory record Official record
Conditions
Familial Adenomatous Polyposis (FAP)
Interventions
eRapa (encapsulated rapamycin), Placebo
Drug
Lead sponsor
Rapamycin Holdings Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
18
States / cities
Arcadia, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 15, 2026, 2:04 AM EDT
Not listed Phase 2 Interventional

Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism

NCT00110708
View directory record Official record
Conditions
Autism, Autistic Disorder, Child Development Disorders, Pervasive, Gastrointestinal Diseases, Signs and Symptoms, Digestive
Interventions
Oralgam (human immunoglobulin)
Drug
Lead sponsor
PediaMed Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
22
States / cities
Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2006 · Synced Oct 15, 2026, 2:04 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Post-tonsillectomy Pain Control in Adults

NCT02358850
View directory record Official record
Conditions
Pain, Postoperative, Postoperative Nausea and Vomiting, Postoperative Hemorrhage, Body Weight Changes
Interventions
Norco (Hydrocodone and Acetaminophen), Percocet (Oxycodone and Acetaminophen), Dilaudid (hydromorphone), Tylenol (Acetaminophen)
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 15, 2026, 2:04 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

NCT06419374
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Interventions
Pegozafermin, Placebo
Biological · Drug
Lead sponsor
89bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
150
States / cities
Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Indomethacin in Chronic Pancreatitis

NCT04207060
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Indomethacin, Placebo, Endoscopy for Pancreatic Function Testing
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Rochester, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Not applicable Interventional

Intraluminal Endosonography for Examination of the Structural Changes of the Stomach in Gastroparetic Patients

NCT01916460
View directory record Official record
Conditions
Idiopathic Gastroparesis, Diabetic Gastroparesis
Interventions
Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)
Procedure
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 1 Interventional

Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286

NCT05180162
View directory record Official record
Conditions
Liver Fibrosis, Pulmonary Fibrosis, Myocardial Fibrosis
Interventions
68Ga-FAP-2286, Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Thomas Hope
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 15, 2026, 2:04 AM EDT
Not yet recruiting Phase 1 Interventional

S-Adenosylmethionine (SAMe) for Chemoprevention of Colorectal Adenomas

NCT07582003
View directory record Official record
Conditions
Colorectal Cancer (Diagnosis), Adenoma
Interventions
S-Adenosylmethionine (SAMe)
Drug
Lead sponsor
Jun Gong, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Glucagon on Hepatic Metabolism

NCT05500586
View directory record Official record
Conditions
Obesity, Type2diabetes, NAFLD
Interventions
Glucagon response study
Drug
Lead sponsor
Adrian Vella
Other
Eligibility
25 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 15, 2026, 2:04 AM EDT
Withdrawn No phase listed Observational

Olanzapine for the Treatment of Refractory Chronic Nausea and Vomiting

NCT02977741
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Olanzapine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Not applicable Interventional

Effects of a Low Glycemic Load Diet on Fatty Liver in Children

NCT00480922
View directory record Official record
Conditions
Hepatic Steatosis
Interventions
Low glycemic load diet, Low fat diet
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2011 · Synced Oct 15, 2026, 2:04 AM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk

NCT05028829
View directory record Official record
Conditions
Liver Fibroses, Cirrhosis
Interventions
Atorvastatin 20mg, Placebo
Drug
Lead sponsor
Raymond Chung
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
2
States / cities
Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 3 Interventional

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

NCT01804829
View directory record Official record
Conditions
Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human, Liver Cirrhosis
Interventions
Civacir® 10%
Biological
Lead sponsor
Biotest Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
23
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Not applicable Interventional

Japanese National Computed Tomographic (CT) Colonography Trial

NCT00997802
View directory record Official record
Conditions
Colonic Polyps, Colonic Neoplasms
Interventions
CT colonography and optical colonoscopy
Device
Lead sponsor
Japanese CT Colonography Society
Other
Eligibility
20 Years and older
Enrollment
1,257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose Escalating Study to Assess the Safety and Tolerability of GT-001

NCT03490786
View directory record Official record
Conditions
Feeding and Eating Disorders
Interventions
GT-001
Drug
Lead sponsor
Gila Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 4 Interventional

Sacral Nerve Stimulation for Anal Incontinence and Bowel Control

NCT00200005
View directory record Official record
Conditions
Fecal Incontinence and Constipation
Interventions
Type: Implantable neurostimulator; InterStim
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis

NCT02025751
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
Metoclopramide Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
Evoke Pharma
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
49
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 15, 2026, 2:04 AM EDT